Table S1.
Correlations between epithelial-to-mesenchymal transition/cancer stem cell markers and clinicopathological characteristics
Characteristics | Total | E-cadherin
|
p-value | Total | N-cadherin
|
p-value | Total | Sox-2
|
p-value | Total | Oct-4
|
p-value | Total | Nanog
|
p-value | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low | High | Low | High | Low | High | Low | High | Low | High | |||||||||||
Gender | 0.761 | 0.892 | 0.621 | 0.279 | 0.434 | |||||||||||||||
Female | 122 | 74 | 48 | 122 | 60 | 62 | 122 | 69 | 53 | 122 | 72 | 50 | 122 | 86 | 36 | |||||
Male | 158 | 93 | 65 | 158 | 79 | 79 | 158 | 94 | 64 | 158 | 83 | 75 | 158 | 118 | 40 | |||||
Age | 0.960 | 0.607 | 0.878 | 0.892 | 0.559 | |||||||||||||||
≤65 years | 111 | 66 | 45 | 111 | 53 | 58 | 111 | 64 | 47 | 111 | 62 | 49 | 111 | 83 | 28 | |||||
>65 years | 169 | 101 | 68 | 169 | 86 | 83 | 169 | 99 | 70 | 169 | 93 | 76 | 169 | 121 | 48 | |||||
Tumor location | 0.708 | 0.117 | 0.748 | 0.803 | 0.538 | |||||||||||||||
Rectal | 130 | 76 | 54 | 130 | 58 | 72 | 130 | 77 | 53 | 130 | 73 | 57 | 130 | 97 | 33 | |||||
Colon | 150 | 91 | 59 | 150 | 81 | 69 | 150 | 86 | 64 | 150 | 82 | 68 | 150 | 107 | 43 | |||||
Tumor size | 0.297 | 0.233 | 0.904 | 0.664 | 0.731 | |||||||||||||||
≤5 cm | 214 | 124 | 90 | 214 | 102 | 112 | 214 | 125 | 89 | 214 | 120 | 94 | 214 | 157 | 57 | |||||
>5 cm | 66 | 43 | 23 | 66 | 37 | 29 | 66 | 38 | 28 | 66 | 35 | 31 | 66 | 47 | 19 | |||||
Tumor differentiation | 0.555 | 0.311 | 0.422 | 0.992 | 0.134 | |||||||||||||||
Poor | 74 | 42 | 32 | 74 | 33 | 41 | 74 | 46 | 28 | 74 | 41 | 33 | 74 | 49 | 25 | |||||
Well/moderate | 206 | 125 | 81 | 206 | 106 | 100 | 206 | 117 | 89 | 206 | 114 | 92 | 206 | 155 | 51 | |||||
Tumor invasion | 0.275 | 0.555 | 0.630 | 0.120 | 0.010 | |||||||||||||||
T1–T2 | 96 | 53 | 43 | 96 | 50 | 46 | 96 | 54 | 42 | 96 | 47 | 49 | 96 | 79 | 17 | |||||
T3–T4 | 184 | 114 | 70 | 184 | 89 | 95 | 184 | 109 | 75 | 184 | 108 | 76 | 184 | 125 | 59 | |||||
Lymph node metastasis | 0.029 | 0.024 | 0.046 | 0.609 | 0.003 | |||||||||||||||
N1 | 81 | 39 | 42 | 81 | 31 | 50 | 81 | 43 | 38 | 81 | 45 | 36 | 81 | 59 | 22 | |||||
N2a | 95 | 58 | 37 | 95 | 56 | 39 | 95 | 65 | 30 | 95 | 56 | 39 | 95 | 80 | 15 | |||||
N2b | 104 | 70 | 34 | 104 | 52 | 52 | 104 | 55 | 49 | 104 | 54 | 50 | 104 | 65 | 39 | |||||
Distant metastasis | 0.039 | 0.012 | 0.396 | <0.001 | 0.118 | |||||||||||||||
Absent | 218 | 123 | 95 | 218 | 117 | 101 | 218 | 124 | 94 | 218 | 134 | 84 | 218 | 154 | 64 | |||||
Present | 62 | 44 | 18 | 62 | 22 | 40 | 62 | 39 | 23 | 62 | 21 | 41 | 62 | 50 | 12 | |||||
Ki-67 positivity | 0.042 | 0.382 | 0.483 | 0.394 | 0.041 | |||||||||||||||
<30% | 78 | 54 | 24 | 78 | 42 | 36 | 78 | 48 | 30 | 78 | 40 | 38 | 78 | 50 | 28 | |||||
≥30% | 202 | 113 | 89 | 202 | 97 | 105 | 202 | 115 | 87 | 202 | 115 | 87 | 202 | 154 | 48 | |||||
Serum CEA level | 0.199 | 0.971 | 0.174 | 0.764 | 0.276 | |||||||||||||||
≤5 ng/mL | 99 | 54 | 45 | 99 | 49 | 50 | 99 | 63 | 36 | 99 | 56 | 43 | 99 | 76 | 23 | |||||
>5 ng/mL | 181 | 113 | 68 | 181 | 90 | 91 | 181 | 100 | 81 | 181 | 99 | 82 | 181 | 128 | 53 | |||||
BMI | 0.472 | 0.887 | 0.367 | 0.394 | 0.166 | |||||||||||||||
<18.5 kg/m2 | 22 | 12 | 10 | 22 | 12 | 10 | 22 | 14 | 8 | 22 | 11 | 11 | 22 | 13 | 9 | |||||
18.5–24.99 kg/m2 | 178 | 111 | 67 | 178 | 88 | 90 | 178 | 98 | 80 | 178 | 104 | 74 | 178 | 128 | 50 | |||||
≥25.0 kg/m2 | 80 | 44 | 36 | 80 | 39 | 41 | 80 | 51 | 29 | 80 | 40 | 40 | 80 | 63 | 17 |
Abbreviations: CEA, carcinoembryonic antigen; BMI, body mass index.